Zoetis (NYSE:ZTS) Hits New 1-Year Low – Here’s What Happened

Zoetis Inc. (NYSE:ZTS)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $71.00 and last traded at $72.1710, with a volume of 1329056 shares changing hands. The stock had previously closed at $73.79.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup cut their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $109.62.

Zoetis Price Performance

The stock has a fifty day moving average of $76.30 and a 200-day moving average of $98.84. The firm has a market capitalization of $29.87 billion, a P/E ratio of 11.93, a PEG ratio of 1.28 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.19 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 34.93%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the last quarter. BlackRock Inc. raised its position in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the last quarter. J. Stern & Co. LLP lifted its stake in shares of Zoetis by 12,431.2% during the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. State Street Corp boosted its holdings in Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after acquiring an additional 149,382 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Zoetis by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.